2型糖尿病临床路径管理初探(1)
 |
| 第1页 |
参见附件(1699KB，3页)。
中图分类号：R587.1 文献标识 码：A 文章编号：1009_816X(2010)02_0097_03
Investigation on the Effectivity of Management of Clinical Pathway inType 2 Diabetes Patients.NING Fan, ZENG Wen_heng, TANG Ke_ke， et al. Department of Endocrinology, SecondAffiliated Hospital of Medical School， Zhejiang University, Zhejiang 310009，C hina
[Abstract] ObjectiveTo observe the effect of the clinical management pathway on the glycemic controland pancreatic β cell function in type 2 diabetes patients.MethodsAn open controlled reality research method was adopted in this study.According to CDS guideline, 107 Outpatients with type 2 diabetes were divided i nto two groups. Group A： BMI≥24Kg/m2， metformin plus insulin sensitizer ag ent was used, and group B: BMI≤24Kg/m2, metformin plus insulin secretion pro moting agents was used. The average follow_up was 1.5 years. The fasting bloodglucose (FBG), 2 hours postprandial blood glucose (2hPBG), glycosylated hemoglob in A1c (HbA1c), fasting insulin (FINS), 2 hours postprandial insulin (2hINS)、 serum lipids (TG, LDL_C, and HDL_C), HOMA_IR, HOMA_IS, and HOMA_IAI were compare d between before (baseline) and after treatment for two groups.Results Comparedto baseline, the levels of FBG、2hPBG、HbA1c were decreased significantly in bot h group A and B (P<0.05). The rate of good HbA1c control (HbA1c value < 6.5%) wassignificantly increased (70.37% vs 55.5% in group A, 65.96% vs 48.94% in gr oupB, respectively). HOMA_IAI were significantly increased(P<0.05)while HOM A_IRdecreased (P<0.05) in Group A. HOMA_IAI and HOMA_IS were significantly incr eased while HOMA_IR decreased (P<0.05～0.01) in Group B. ConclusionsThe rates of good control in HbA1c and pancreatic β cell function were signific antly improved in patients with type 2 diabetes mellitus under the management ofclinical pathway.
[Key words] Type 2 diabetes mellitus； Insulin secretion promo ting agents； Insulin sensitizer； Management of clinical pathway ......
您现在查看是摘要介绍页，详见PDF附件(1699KB，3页)。